Open an account

NovaBridge Biosciences.

IMAB · NASDAQ

$1.43+$0.125 (+9.62%)TodayMarket closed ·
Prev close $1.30

Latest news

  • Press releaseGlobe Newswire

    I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

  • Press releaseGlobe Newswire

    I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

  • Press releaseGlobe Newswire

    I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

  • Press releasePRNewswire

    Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

  • Press releaseGlobe Newswire

    I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

  • Press releasePRNewswire

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

  • NewsAvi Kapoor

    C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

  • Press releaseGlobe Newswire

    I-Mab to Participate in September Investor Conferences

  • Press releaseGlobe Newswire

    I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

  • NewsAvi Kapoor

    Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday

  • NewsAvi Kapoor

    Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday

  • Press releaseGlobe Newswire

    I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releasePRNewswire

    Everest Medicines Expands Strategic Investment in I-MAB

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    I-Mab to Join Virtual Biotech Event, Talks Cancer Treatment Progress With Investors

  • Press releaseGlobe Newswire

    I-Mab to Present at the BTIG Virtual Biotechnology Conference

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseGlobe Newswire

    I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

  • Press releaseGlobe Newswire

    I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

  • Press releaseGlobe Newswire

    I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releasePRNewswire

    I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

  • Press releasePRNewswire

    I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

  • Press releasePRNewswire

    I-Mab to Participate at the Piper Sandler Healthcare Conference

  • Press releasePRNewswire

    I-Mab Reports Third Quarter 2024 Results

  • Press releasePRNewswire

    I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

  • Press releasePRNewswire

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

  • Press releasePRNewswire

    I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

  • Press releasePRNewswire

    I-Mab to Participate at the Truist Securities BioPharma Symposium

  • Press releasePRNewswire

    I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

  • Press releasePRNewswire

    I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

  • Press releasePRNewswire

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

  • Press releasePRNewswire

    I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

  • Press releasePRNewswire

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

  • Press releasePRNewswire

    I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

  • Press releasePRNewswire

    I-Mab Announces Leadership Transitions

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.